April 25th 2024
Findings from the CARTITUDE-2 trial support the use of cilta-cel in patients with multiple myeloma, says Tina Glow, AAS, RN, BSN.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Belantamab Mafodotin-Based Triplet Elicits High Response Rates, Appears Suitable in Myeloma
December 8th 2020The ongoing phase 1/2 DREAMM-6 trial found that the addition of belantamab mafodotin to bortezomib and dexamethasone elicited high response rates and a suitable safety profile in patients with relapsed or refractory multiple myeloma.
ALLO-715, Off-the-Shelf CAR T-Cell Therapy, Produces Early Promise in Multiple Myeloma
December 7th 2020An off-the-shelf CAR T-cell therapy that targets B-cell maturation antigen, ALLO-715, elicited responses in heavily pretreated patients with relapsed/refractory multiple myeloma in early findings from a first-in-human study presented at the 2020 ASH Meeting.
Addition of Subcutaneous Daratumumab to Pd Improves Clinical Benefit in RRMM
December 6th 2020The combination induced low rates of infusion-related reaction, and had a shorter administration duration, increasing convenience for patients and decreasing treatment burden, according to Meletios A. Dimopoulos, MD.
Cita-Cel Induces High Response Rate in Relapsed/Refractory Multiple Myeloma
December 6th 2020Treatment with the CAR T-cell therapy ciltacabtagene autoleucel led to a high response rate and an acceptable safety profile at the recommended phase 2 dose in patients with relapsed or refractory multiple myeloma.
Selinexor, Bortezomib, Dexamethasone Combination Effective for Patients with Multiple Myeloma
November 27th 2020The phase 3 BOSTON study suggested that a once-per-week combination regimen of selinexor (Xpovio), bortezomib (Velcade), and dexamethasone (Ozurdex) is an effective treatment option for patients with multiple myeloma who have received 1 to 3 previous lines of therapy.
Study Analyzing Daratumumab to Treat Patients with Multiple Myeloma Induces Positive Topline Results
October 22nd 2020Genmab recently announced positive topline results from part 2 of the Phase 3 CASSIOPEIA study examining daratumumab monotherapy as maintenance therapy to treat patients diagnosed with multiple myeloma.
FDA Grants Priority Review to Idecabtagene Vicleucel for Multiple Myeloma
September 22nd 2020The biologics license application for idecabtagene vicleucel is for the treatment of adult patients with multiple myeloma who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.
Phase 3 TOURMALINE-MM2 Fails to Meet Primary End Point of PFS
September 10th 2020The study is evaluating the addition of ixazomib (Ninlaro) to lenalidomide and dexamethasone versus lenalidomide and dexamethasone plus placebo in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
Phase 2 CLOVER-1 Study Shows Promise for Patients with Triple Class Refractory Multiple Myeloma
September 9th 2020A clinically meaningful 40% overall response rate was seen in a subset of patients with triple class refractory multiple myeloma who received CLR 131 at a total administered dose of 60 mCi or greater.
FDA Grants Priority Review to Melflufen in Combination with Dexamethasone for Myeloma
August 31st 2020The new drug application is seeking approval for the treatment of adult patients with multiple myeloma whose disease is refractory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-CD-38 monoclonal antibody.
FDA Approves Daratumumab, Carfilzomib, Dexamethasone Triplet to Treat Multiple Myeloma
August 21st 2020The FDA approved daratumumab in combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 previous lines of therapy.
Daratumumab Combo Meets Primary End Point in Relapsed/Refractory Multiple Myeloma
August 3rd 2020The study is evaluating the subcutaneous formulation of daratumumab in combination with pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone as treatment for patients with relapsed or refractory multiple myeloma.